Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease
Chagas disease (CD) is a parasitary disease caused by Trypanosoma cruzi. Treatment is indicated in children, reactivations in immunosuppressed patients and chronic Chagas without evident pathology. Poor tolerance and presentation of adverse reactions (AR) make it ineffective. ARs are due to oxi...
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/39043 |
| Aporte de: |
| id |
I10-R327-article-39043 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
chagas' s disease treatment ascorbic acid enfermedad de chagas tratamiento ácido ascórbico |
| spellingShingle |
chagas' s disease treatment ascorbic acid enfermedad de chagas tratamiento ácido ascórbico Montamat, MM Brito, BR Budini, BP Rivarola, RW Paglini, PA Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| topic_facet |
chagas' s disease treatment ascorbic acid enfermedad de chagas tratamiento ácido ascórbico |
| author |
Montamat, MM Brito, BR Budini, BP Rivarola, RW Paglini, PA |
| author_facet |
Montamat, MM Brito, BR Budini, BP Rivarola, RW Paglini, PA |
| author_sort |
Montamat, MM |
| title |
Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| title_short |
Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| title_full |
Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| title_fullStr |
Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| title_full_unstemmed |
Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| title_sort |
role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease |
| description |
Chagas disease (CD) is a parasitary disease caused by Trypanosoma cruzi. Treatment is indicated in children, reactivations in immunosuppressed patients and chronic Chagas without evident pathology. Poor tolerance and presentation of adverse reactions (AR) make it ineffective. ARs are due to oxidative stress. Animal studies found that ascorbic acid (aa) can attenuate these effects. The administration of aa with the antiparasitic treatment would contribute to attenuate ARs, facilitating compliance and efficacy. The objectives were: to identify AR secondary to the antiparasitic; compare the prevalence of AR in patients receiving associated aa versus standard treatment.
This is an open randomized controlled experimental study. Population: patients with CD without apparent pathology.GI antiparasitic treatment; GII: antiparasitic + aa. Study period: June 2019/June 2022.
Eighteen patients were included, 22% male, mean age: 34 years. Educational level: 5.5% were illiterate, 22% have completed primary school, 33% have not finished primary school. 28% have started but not finished secondary school whereas 11% completed it. Eight patients were assigned to GI and 10 to GII. They presented the following ARs: GI: asthenia 11% of them (50% moderate intensity (Mo) and 50% mild (Mi)) GII 5.5% Mi, GI distension 11% Mi, GI colic 16.5% (11% M 5, 5% Mi), epigastric pain GI 27.5% (22% M and 5.5% Mi) GII 5.5% Mi, nausea GI 28% (23% M and 5% Mi) GII 16.5% Mi, diarrhea GI 11% Mi GII 5.5% Mi, GI vomits 5.5% Mi, anorexia GI 16.5% M GII 5.5% M, GII paresthesias 5.5% Mi, dizziness GI 22% (16, 5%M 5.5%Mi), headache GI 27.5% (16.5%M and 11% Mi) GII 22% M, rash GI 22% ( 5.5% severe (S) 16.5% M), GII 22% (11% M 11% Mi), eosinophilia GI 11% Mi GII 11% M.
In conclusion, the middle-aged female sex with a low educational level predominated. The most frequent ARs were digestive followed by exanthema with greater intensity in GI. The study is still opened for the recruitment patients in order to determine if the differences found in this preliminary report are statistically significant.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/39043 |
| work_keys_str_mv |
AT montamatmm roleofascorbicacidinthepresentationofadversereactionssecondarytotreatmentinchagasdisease AT britobr roleofascorbicacidinthepresentationofadversereactionssecondarytotreatmentinchagasdisease AT budinibp roleofascorbicacidinthepresentationofadversereactionssecondarytotreatmentinchagasdisease AT rivarolarw roleofascorbicacidinthepresentationofadversereactionssecondarytotreatmentinchagasdisease AT paglinipa roleofascorbicacidinthepresentationofadversereactionssecondarytotreatmentinchagasdisease AT montamatmm roldelacidoascorbicoenlapresentaciondereaccionesadversassecundariasaltratamientoantiparasitarioenpacientesconenfermedaddechagas AT britobr roldelacidoascorbicoenlapresentaciondereaccionesadversassecundariasaltratamientoantiparasitarioenpacientesconenfermedaddechagas AT budinibp roldelacidoascorbicoenlapresentaciondereaccionesadversassecundariasaltratamientoantiparasitarioenpacientesconenfermedaddechagas AT rivarolarw roldelacidoascorbicoenlapresentaciondereaccionesadversassecundariasaltratamientoantiparasitarioenpacientesconenfermedaddechagas AT paglinipa roldelacidoascorbicoenlapresentaciondereaccionesadversassecundariasaltratamientoantiparasitarioenpacientesconenfermedaddechagas |
| first_indexed |
2024-09-03T21:04:03Z |
| last_indexed |
2024-09-03T21:04:03Z |
| _version_ |
1809210349367328768 |
| spelling |
I10-R327-article-390432024-04-15T16:14:45Z Role of ascorbic acid in the presentation of adverse reactions secondary to treatment in chagas disease Rol del ácido ascórbico en la presentación de reacciones adversas secundarias al tratamiento antiparasitario en pacientes con enfermedad de Chagas Montamat, MM Brito, BR Budini, BP Rivarola, RW Paglini, PA chagas' s disease treatment ascorbic acid enfermedad de chagas tratamiento ácido ascórbico Chagas disease (CD) is a parasitary disease caused by Trypanosoma cruzi. Treatment is indicated in children, reactivations in immunosuppressed patients and chronic Chagas without evident pathology. Poor tolerance and presentation of adverse reactions (AR) make it ineffective. ARs are due to oxidative stress. Animal studies found that ascorbic acid (aa) can attenuate these effects. The administration of aa with the antiparasitic treatment would contribute to attenuate ARs, facilitating compliance and efficacy. The objectives were: to identify AR secondary to the antiparasitic; compare the prevalence of AR in patients receiving associated aa versus standard treatment. This is an open randomized controlled experimental study. Population: patients with CD without apparent pathology.GI antiparasitic treatment; GII: antiparasitic + aa. Study period: June 2019/June 2022. Eighteen patients were included, 22% male, mean age: 34 years. Educational level: 5.5% were illiterate, 22% have completed primary school, 33% have not finished primary school. 28% have started but not finished secondary school whereas 11% completed it. Eight patients were assigned to GI and 10 to GII. They presented the following ARs: GI: asthenia 11% of them (50% moderate intensity (Mo) and 50% mild (Mi)) GII 5.5% Mi, GI distension 11% Mi, GI colic 16.5% (11% M 5, 5% Mi), epigastric pain GI 27.5% (22% M and 5.5% Mi) GII 5.5% Mi, nausea GI 28% (23% M and 5% Mi) GII 16.5% Mi, diarrhea GI 11% Mi GII 5.5% Mi, GI vomits 5.5% Mi, anorexia GI 16.5% M GII 5.5% M, GII paresthesias 5.5% Mi, dizziness GI 22% (16, 5%M 5.5%Mi), headache GI 27.5% (16.5%M and 11% Mi) GII 22% M, rash GI 22% ( 5.5% severe (S) 16.5% M), GII 22% (11% M 11% Mi), eosinophilia GI 11% Mi GII 11% M. In conclusion, the middle-aged female sex with a low educational level predominated. The most frequent ARs were digestive followed by exanthema with greater intensity in GI. The study is still opened for the recruitment patients in order to determine if the differences found in this preliminary report are statistically significant. La enfermedad de Chagas (EC) es una parasitosis causada por Trypanosoma cruzi. El tratamiento está indicado en niños, reactivaciones en inmunodeprimidos y Chagas crónico sin patología evidente. La escasa tolerancia y presentación de reacciones adversas (RA) hacen que sea poco efectivo. Las RA se deben al estrés oxidativo. Estudios en animales encontraron que el ácido ascórbico (aa) puede atenuar dichos efectos. La administración de aa con el tratamiento antiparasitario contribuiría a atenuar las RA facilitando cumplimiento y eficacia. Los objetivos fueron: identificar RA secundarias al antiparasitario; comparar la prevalencia de RA en pacientes que reciben aa asociado versus tratamiento estándar. Se trata de un estudio experimental abierto aleatorizado controlado. Población: pacientes con EC sin patología aparente.GI tratamiento antiparasitario; GII: antiparasitario + aa. Período de estudio: Junio 2019/ junio 2022. Se incluyeron 18 pacientes, 22% varones, edad promedio 34 años. Nivel educativo: 5,5% analfabetos, 22% primaria completa, 33% incompleta, 28% secundario incompleto, 11% completo. 8 pacientes se asignaron a GI y 10 a GII. Presentaron las siguientes RA: astenia GI 11% de ellos 50% intensidad moderada (M) y 50% leve (L) GII 5,5% L, distensión GII 11% L, cólicos GI 16,5% (11%M 5,5% L), epigastralgia GI 27,5% (22% M y 5,5% L) GII 5,5% L, náuseas GI 28% (23% M y 5%L) GII 16,5% L, diarrea GI 11% L GII 5,5% L, vómitos GI 5,5% L, anorexia GI 16,5% (M GII 5,5% M), parestesias GII 5,5% L, mareos GI 22% (16,5%M 5,5%L), cefalea GI 27,5% (16,5%M y 11% L) GII 22% M, exantema GI 22% 5,5 severa (S) 16,5% M, GII 22% (11%M 11%L), eosinofilia GI 5,5% L GII 16,5% (5,5%M 11% L). Como conclusión predomino el sexo femenino de mediana edad con un nivel educativo bajo.Las RA mas frecuentes fueron digestivas seguidas de exantema con mayor intensidad en el GI. El estudio continúa reclutando pacientes para determinar si las diferencias encontradas en este informe preliminar son estadísticamente significativas. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-10-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto https://revistas.unc.edu.ar/index.php/med/article/view/39043 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. Suplemento JIC XXIII (2022): Suplemento JIC XXIII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |